BBIO: Other company developments

Item 8.01. Other Events On May 12, 2026, BridgeBio Pharma, Inc. issued a press release titled “BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release titled “BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1” 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BridgeBio Pharma, Inc. Date: May 13, 2026 By: /s/ Thomas Trimarchi Thomas Trimarchi, Ph.D. President and Chief Financial Officer